Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain.
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease.
Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma.
Celgene Corp. earlier this week announced that the Food and Drug Administration approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis. The drug is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis, according to the company.
AbbVie on Thursday announced that the Food and Drug Administration approved Humira (adalimumab) as a treatment for pediatric Crohn's disease patients ages 6 years and older when other treatments haven't worked well enough.
In celebration of the 30th anniversary of the enactment of the Drug Price Competition and Patent Term Restoration Act, also known as the “Hatch-Waxman” Act, the National Association of Chain Drug Stores issued a statement to reflect on the evolution of providing patient access to generic medications and noted that it is looking forward to further progress in the years ahead.
In honor of the 30th anniversary of the Drug Price Competition and Patent Term Restoration Act — more commonly known as the Hatch Waxman Act — which enabled manufacturers to bring generic versions of pharmaceuticals to market more easily, GPHA president Ralph Neas issued a statement.
The National Association of Chain Drug Stores has offered its support for new legislation — S. 2862, the Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 — which calls for a collaborative, coordinated approach to curbing prescription drug abuse and safeguarding patients.